Cancer immunotherapy company Compugen Ltd (NASDAQ:CGEN) disclosed on Monday that it recorded a net loss of USD8.4m (USD0.14 per basic and diluted share) for the first quarter ended 31 March 2019.
This marks a decline in earnings when compared with a net income of USD0.1m (USD0.0 per basic and diluted share) in the comparable period of 2018.
Revenues of USD0 were generated for the first quarter of 2019, down over USD10m in the comparable period of 2018. The revenues for the first quarter of 2018 reflect the upfront payment of USD10m from the license agreement with MedImmune/AstraZeneca.
R&D expenses of USD6.3m were recorded for the first quarter ended 31 March 2019, from R&D of USD7.1m for the comparable period in 2018. The decrease in R&D expenses is attributed to the cost reduction measures announced during the first quarter of 2019. Further reduction in expenses will be reflected over the course of 2019.
Acerus and Aytu Bioscience to Co-promote Natesto in the United States
Amgen reports financial results for Q2 2019
Pfizer to integrate Upjohn with Mylan to establish new global pharmaceutical company
Neurocrine Biosciences reports half-year ended 30 June 2019 financial results
Thermo Fisher Scientific reports financial results for Q2 2019
Veloxis Pharmaceuticals revises 2019 outlook
NANOBIOTIX collects revenues of EUR31.9,000 for Q2 2019
Seattle Genetics incurs net loss of USD79.2m in Q2 2019
Baxter's board announces USD0.22 per share dividend pay order
Johnson & Johnson declares dividend of USD0.95 per share for Q3 2019
Sun Pharma Launches Ezallor Sprinkle in the US for People Who Have Difficulty Swallowing
PanTheryx Aims to End Diarrheal Disease in Cambodia
CCA Industries Inc swings to income of USD349,320 for Q2 2019
Oncimmune Holdings signs commercial collaboration with R-Pharm JSC